Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD) for $800 million upfront in a deal that could have a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback